Biocon - Global Healthcare Company
 
About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
Biocon History
  > ABOUT US
  Overview
  Businesses
  Fact Sheet
  Mission
  People
  Quality
  History
  Awards
  Strategic Alliances
  Biocon in Malaysia
  
  Home
  
     
 

History

November 29, 1978

Biocon’s Founding Day - the start of a biorevolution in India. Over the years, Biocon has evolved from an enzyme-manufacturing company into a fully integrated biopharmaceutical enterprise. Today, we leverage a formidable combination of proprietary fermentation technologies and research skills to develop affordable therapy for unmet medical needs.

Biocon India is incorporated as a joint venture between Biocon Biochemicals Ltd. of Ireland and an Indian entrepreneur, Kiran Mazumdar-Shaw


1979


Biocon is the first Indian company to manufacture and export enzymes to USA and Europe


1989


Unilever plc. acquires Biocon Biochemicals Ltd. in Ireland and merges it with its subsidiary, Quest International

Biocon is the first Indian biotech company to receive US funding for proprietary technologies


1990


Biocon scales up its in-house research programme, based on a proprietary solid substrate fermentation technology, from pilot to plant level


1993


Biocon's R&D and manufacturing facilities receive ISO 9001 certification from RWTUV, Germany


1994


Biocon establishes Syngene International Pvt. Ltd. as a Custom research Company (CRC) to address the growing need for outsourced R&D in the pharmaceutical sector


1996


The commercial success of Biocon's proprietary fermentation plant leads to a 3-fold expansion

Biocon leverages its technology platform to enter biopharmaceuticals and statins


1997


Biocon spearheads initiatives in human healthcare through a dedicated manufacturing facility


1998


Unilever inks a deal with ICI to sell its specialty chemicals division of which Quest International is a part. Unilever agrees to sell its shareholding in Biocon to the Indian promoters. Biocon becomes an independent entity


2000


Biocon commissions its first fully automated submerged fermentation plant to produce specialty pharmaceuticals

Biocon establishes Clinigene, India's first Clinical Research Organisation (CRO) to pursue clinical research and development


2001


Biocon becomes the first Indian company to be approved by US FDA for the manufacture of lovastatin, a cholesterol-lowering molecule

Biocon's proprietary bioreactor, PlaFractor™ is granted a US 2001 and world-wide patent


2002


Clinigene's clinical laboratory is the first in India to receive CAP accreditation


2003


Biocon is the first company worldwide to develop human insulin on a Pichia expression system


2004


Biocon creates a buzz in the stock market in March 2004 with its hugely successful IPO. Day 1 on the bourses closes with a market value of $1.11 billion, making Biocon only the second Indian company to cross the $1 billion mark on the first day of listing.

Syngene establishes new research centre

Biocon Limited, announced the launch of INSUGEN®, the new generation bio-insulin, manufactured in Asia's largest human insulin plant.

Biocon Limited and Vaccinex, Inc. announce a broad strategic partnership to discover and co-develop at least four therapeutic antibody products.

2005

Biocon signs a commercial agreement for supply of insulin API to Asia, Africa and the Middle East.


2006


Biocon inaugurates Biocon Biopharmaceuticals, India's largest multi-product Biologics facility at Biocon Park

Biocon inaugurates Biocon Park, India's largest integrated biotechnology hub, comprising an integrated cluster of research laboratories and manufacturing facilities spread across 90 acres in KIADB (Karnataka Industrial Areas Development Board) industrial estate.

Biocon announced a licensing agreement with Bayer HealthCare (BHC) for the exclusive marketing and trademark rights for INSUGEN® for the Chinese market.

Syngene and Innate Pharmaceuticals AB, Umea, Sweden conclude a cooperation agreement to jointly develop, manufacture and market virulence blockers to counteract bacterial diarrhoeal disease.

Biocon launches India's first anti-cancer drug BIOMAb EGFR®.


2007


Biocon and Abu Dhabi based pharmaceutical company Neopharma sign an MOU to establish a JV to manufacture and market a range of biopharmaceuticals for the GCC countries (Gulf Cooperation Council).

Biocon grants exclusive license to Ferozsons Laboratories Limited for marketing BIOMAb EGFR® in Pakistan.

Biocon announced the launch of its Nephrology Division and a comprehensive portfolio of renal therapy products.

Syngene enters into a research partnership with Bristol-Myers Squibb and completes the ground breaking ceremony of new research facility at Biocon Park.

Biocon signs Memorandum of Understanding with Deakin University, Australia. To establish Deakin Research Institute in Bangalore

Biocon divests enzymes division for USD 115 million to Novozymes. Biocon business portfolio to focus on biopharmaceuticals

Biocon and Abraxis BioScience, announce an agreement wherein Abraxis will license the right to develop a biosimilar version of G-CSF (Granulocyte-Colony Stimulating Factor) in North America and the European Union.

Biocon and Neopharma sign an MoU to establish Neobiocon, a joint venture company in Dubai's biotechnology and research park, Dubiotech.

Biocon and Abraxis BioScience Inc., announce a licensing agreement for the commercialization of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in India.

Biocon presents the results of Phase 1 studies on its oral insulin product, IN-105 at the European Association for Study of Diabetes (EASD) meeting held at Amsterdam.


2008


Biocon acquires a 78% stake in German pharmaceutical company, AxiCorp GmbH for a consideration of €30 Million

Biocon launches a Safety Device in the form of pre-filled syringes for two of its life saving products, GCSF (granulocyte-colony stimulating factor) and EPO (Erythropoietin) in collaboration with Safety Syringes Inc. ERYPRO Safe and NUFIL Safe are the first two drugs that will marketed using this novel device with other injectable products to follow in the future.

Biocon and Abraxis Bioscience launch ABRAXANE in India for treatment of Breast Cancer.

Biocon is ranked among the top 20 global biotechnology companies (Med Ad News).

Biocon is the 7th largest biotech employer in the world (Med Ad News).

Biocon announced the results of an ascending dose study on its oral insulin drug (IN-105) at the European Association for the Study of Diabetes (EASD) meeting in Rome.

NeoBiocon and Abraxis Bioscience launch Abraxane in The UAE for the treatment of Breast Cancer.


2009


Biocon's Syngene partners with Sapient Discovery to expand integrated drug discovery offerings

Biocon's Syngene and DuPont Crop Protection Forge Alliance Partnership

Bristol-Myers Squibb and Biocon's Syngene open new R&D Facility at Biocon Park

Biocon launches BASALOG - long lasting basal insulin for Type 1 & Type 2 Diabetics

Biocon inks partnership with ISB to launch the Biocon Cell for Innovation Management

Biocon announced Strategic Collaboration with Mylan to enter the Global Generic Biologics Market

Biocon Limited and Amylin Pharmaceuticals entered into a Global Development and Commercialization Agreement for a Novel Peptide Hybrid. The Program will focus on the potential treatment of diabetes.

Biocon and HCG group of hospitals join hands to fight against cervical


2010

Biocon explores investment in Malaysia in partnership with BiotechCorp

Biocon and Bayer join hands to create awareness for self monitoring for diabetics

Syngene and Endo Pharmaceuticals, USA  to  jointly discover and develop novel biological drug molecules to fight cancer

Biocon acquires stake of its Cuban partner CIMAB S.A. in their seven year old JV, Biocon Biopharmaceuticals Pvt. Ltd

Biocon and Optimer Pharmaceuticals announce manufacturing and supply agreement for a novel API, first-in-class anti-infective (C. difficile)

Biocon and the Center of Molecular Immunology (CIM), based in Havana, Cuba strengthen their existing research   partnership by joining forces for an integrated antibody program in immunology

Biocon announced a strategic foreign direct investment in Malaysia with the Malaysian Biotechnology Corporation SdnBhd (BiotechCorp)


2011

Biocon divests its stake in its German subsidiary, AxiCorp GmbH, to the existing group of promoter shareholders, AxiCorp was the licensee for Biocon's biosimilar Insulin and Glargine in Germany and had the sole responsibility for commercializing these products. As a consequence of this divestment, these rights revert to Biocon.

Biocon announced project commencement for first high-end biopharmaceutical manufacturing and R&D facility in Bio-XCell, Malaysia

Biocon launches INSUPen®, a convenient and affordable reusable insulin delivery device


2012

Biocon announced Positive Results from its Global Phase 3 study with Recombinant Human Insulin

GE Capital invests in Syngene, Biocon's Research Services Subsidiary

Biocon announced Positive Efficacy Data from Phase 3 clinical study with its Novel Monoclonal Antibody, Itolizumab for Psoriasis

Syngene - a subsidiary of Biocon Group, in collaboration with Abbott, setup a dedicated Nutrition Research and Development Center at Biocon Park

Biocon announced positive results from its Phase 1 Comparative PK-PD Study with Biosimilar Insulin Glargine

Biocon: the only Asian Company to Feature in the Global Top 20 BioPharma Employers, by Science Magazine

Biocon enters into an agreement with Bristol-Myers Squibb for its IN-105, an Oral Insulin drug


2013

Biocon received Marketing Authorization from the Drugs Controller General of India (DCGI) for its Novel Biologic Itolizumab, anti CD6 molecule, for the treatment of chronic plaque Psoriasis

Biocon enhances Partnership with Mylan through Strategic Collaboration for Insulin Products

Biocon Delivers a Healthy Growth of 22% driven by strong traction in Biopharma

Biocon Launched ALZUMAb- a 'First in Class' Novel Biologic Treatment for Psoriasis Patients in India

Biocon Partnered with CytoSorbents to Market CytoSorb® - A 'First-in-Class' Therapy for Sepsis Management

Biocon Ranked at No. 6 among Top 20 Global Biotech Employers by the Science Magazine

Biocon Unveils Biocon Academy - A Center of Excellence for Advanced Learning in Applied Biosciences

Biocon & Mylan received Indian Regulatory Approval for Trastuzumab for Treating Breast Cancer

Biocon and Quark Pharmaceuticals Collaborate to Develop Novel siRNA based Therapeutics

Biocon's ALZUMAb wins BioSpectrum BioPharma Product of the Year, 2013

Biocon Academy's Flagship Program in Collaboration with KGI Takes Off to a Flying Start


2014


Biocon has been conferred with the Sir J C Bose Memorial Award – 2013 (Institutional category) by Indian Science Monitor (ISM) for its contribution in the field of Biotechnology, with special reference to the launch of ALZUMAb (Itolizumab)

Biocon introduced CANMAb - Trastuzumab for Treating Breast Cancer in India

Syngene, a subsidiary of Biocon Group, in collaboration with Baxter sets up a dedicated Research and Development Center at Biocon Park




 
     
Quality
  Quick links:
    Press Releases
    Discovery Pipeline
    Product Glossary
    Stock Info
     
  Biocon

Businesses

Recommended sites Biocon on  
  Home
About Us

Investor Relations
Media Relations
Careers
Site Map
Our Growth Accelerators
Fact Sheet
Branded Formulations
Biopharmaceuticals
Research Services
Active Discovery Program

ABLE
Karnataka Vision Group on BT
Syngene International
Clinigene International
Biocon Academy

    Linked In   
       
  Report adverse event/side effects and product complaints    
       
  * Disclaimer | Authorised Users               © 2014, Biocon. All Rights Reserved